Acute Pain Treatments

Find Acute Pain Treatments

Generic Name

Clonidine

Brand Names

ONYDA, Clonidine Transdermal, Catapres-TTS-2, Catapres-TTS-3, Catapres-TTS-1, Clonidine HCI, Duraclon, Javadin, Nexiclon

FDA approval date: September 04, 1987

Classification: Central alpha-2 Adrenergic Agonist

Form: Patch, Injection, Tablet, Suspension, Solution

What is ONYDA (Clonidine)?

Clonidine hydrochloride extended-release tablets are indicated for the treatment of attention deficit hyperactivity disorder as monotherapy and as adjunctive therapy to stimulant medications. Clonidine hydrochloride is a centrally acting alpha 2 -adrenergic agonist indicated for the treatment of attention deficit hyperactivity disorder as monotherapy or as adjunctive therapy to stimulant medications.

Approved To Treat

Top Global Experts

View All

Save this treatment for later

Not sure about your diagnosis?

Check Your Symptoms

Tired of the same old research?

Check Latest Advances

Related Clinical Trials

Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs

Enrollment Status: Recruiting

Publish Date: April 06, 2026

Intervention Type: Drug

Summary: The study investigators are interested in learning more about how drugs, that are given to children by their health care provider, act in the bodies of children and young adults in hopes to find the most safe and effective dose for children. The primary objective of this study is to evaluate the PK of understudied drugs currently being administered to children per SOC as prescribed by their treati...

Repurposing Low-Dose Clonidine for PTSD in Veterans

Who is this study for: Patients with Posttraumatic Stress Disorder

Enrollment Status: Recruiting

Publish Date: March 31, 2026

Intervention Type: Drug, Other

Study Drug: Clonidine Pill

Study Phase: Phase 3

Summary: Hypothesis: Veterans with PTSD prescribed clonidine will demonstrate improvements in PTSD symptoms, including daytime, nighttime, and sleep-related behaviors.

Noradrenergic Dysregulation, Sleep and Cognition in Older Adults With Insomnia

Enrollment Status: Recruiting

Publish Date: March 30, 2026

Intervention Type: Other

Study Phase: Not Applicable

Summary: This study investigates the relationship between the noradrenergic (NA) system, sleep quality, and cognitive function in older adults with insomnia - a population at elevated risk for Alzheimer's disease-related dementias (ADRD) - compared to age and sex matched controls with normal sleep. The study characterizes NA function through multiple approaches: measuring 24-hour plasma levels of norepinep...

View All Clinical Trials